PDT Partners LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 20,899 shares of the biopharmaceutical company's stock, valued at approximately $379,000.
A number of other institutional investors have also made changes to their positions in CLDX. Point72 Asset Management L.P. increased its holdings in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after acquiring an additional 847,264 shares during the last quarter. Nuveen LLC acquired a new position in Celldex Therapeutics in the 1st quarter valued at $7,789,000. Vestal Point Capital LP acquired a new position in Celldex Therapeutics in the 4th quarter valued at $7,707,000. TFG Asset Management GP Ltd acquired a new position in Celldex Therapeutics in the 4th quarter valued at $4,852,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Celldex Therapeutics in the 4th quarter valued at $3,905,000.
Celldex Therapeutics Stock Up 0.5%
Shares of CLDX traded up $0.13 during trading hours on Wednesday, hitting $24.43. 221,414 shares of the company were exchanged, compared to its average volume of 1,017,607. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -8.09 and a beta of 1.19. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The firm's fifty day moving average is $22.58 and its 200 day moving average is $20.65.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. Analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.
Analyst Upgrades and Downgrades
CLDX has been the topic of a number of research reports. Citigroup decreased their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Wells Fargo & Company decreased their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating on the stock in a report on Wednesday, August 20th. HC Wainwright decreased their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Finally, Canaccord Genuity Group decreased their price objective on Celldex Therapeutics from $64.00 to $62.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.67.
Read Our Latest Analysis on CLDX
Celldex Therapeutics Company Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
